Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Are These 2 Biotechs About to Be Bought?

This video is part of our "Motley Fool Conversations" series, in which health-care editor/analyst David Williamson discusses topics across the investing world.

In this video, David takes a closer look at two biotechs considered takeover targets. In fact, Amylin recently rebuffed an offer from Bristol-Myers Squibb. Will the large pharma come back with a stronger offer or will another player emerge from the shadows with a deal Amylin can't refuse? Meanwhile, Amarin recieved a patent for its cholesterol-fighting fish-oil-based drug AMR-101, which is pending FDA approval after two successful phase 3 trials. With patent protection in hand and potentially an approval on its way, will a deep-pocketed player with a thin pipeline step up to the plate, or will Amarin attempt to go it alone? Watch and find out.

Health-care investors are always looking for the next big breakthrough. Motley Fool co-founder David Gardner recently identified a small-cap health-care company that he believes is poised for monster returns. To uncover this top pick today, enjoy the special free report: "Discover the Next Rule-Breaking Multibagger." Don't miss out on this limited-time offer and your opportunity to discover this game-changing company before the market does. Click here to access your report -- it's totally free.

David Williamson owns shares of Amarin plc (ADR). The Motley Fool owns shares of GlaxoSmithKline. Motley Fool newsletter services recommend GlaxoSmithKline. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Read/Post Comments (1) | Recommend This Article (6)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On April 06, 2012, at 1:52 PM, rsinj wrote:

    Considering the number of insiders selling and number of shares sold over the past two weeks, there is no buyout any time soon for Amarin.

Add your comment.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1855264, ~/Articles/ArticleHandler.aspx, 10/26/2016 1:25:50 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,211.11 41.84 0.23%
S&P 500 2,139.20 -3.96 -0.18%
NASD 5,261.71 -21.69 -0.41%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

12/31/1969 7:00 PM
AMLN.DL $0.00 Down +0.00 +0.00%
Amylin Pharmaceuti… CAPS Rating: **
AMRN $3.37 Up +0.08 +2.43%
Amarin CAPS Rating: ****
BMY $49.39 Down -0.16 -0.32%
Bristol-Myers Squi… CAPS Rating: ****
GSK $40.37 Up +0.05 +0.12%
GlaxoSmithKline CAPS Rating: ***
LLY $76.57 Down -1.18 -1.52%
Eli Lilly and Co. CAPS Rating: ***